top of page
News, Events and Updates
Search
Anavex CEO Invited to Present at Upcoming Investment Conferences
Jan 7, 2014
The Anticipated Clinical Effect of the new AD Drug ANAVEX 2-73 in a Calibrated Quantitative Systems
Dec 11, 2013
Anavex Appoints Clinical Design Expert to Scientific Advisory Board
Dec 10, 2013
Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
Dec 3, 2013
Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit
Nov 21, 2013
Anavex Announces Expansion of Scientific Advisory Board
Nov 20, 2013
Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of AD
Nov 18, 2013
Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer's Disease
Nov 12, 2013
Blockade of Tau Hyperphosphorylation and Ab1-42 Generation by the Aminotetrahydrofuran Derivative...
Nov 11, 2013
Chronic Treatment with the Tetrahydrofuran Derivative ANAVEX 2-73, a Mixed Muscarinic Cholinergic...
Nov 11, 2013
Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
Nov 7, 2013
39
40
41
42
43
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
